Tizanidine Dosing for Chronic Cervical Radiculopathy
Start tizanidine at 2 mg orally at bedtime, then increase by 2-4 mg every 3-7 days as tolerated, targeting 6-8 mg three times daily (18-24 mg/day total), with a maximum of 36 mg/day if needed for adequate symptom control. 1, 2
Initial Dosing Strategy
Begin with 2 mg at night to assess tolerance, particularly for sedation and hypotension 1, 3. The FDA-approved dosing emphasizes starting at 4 mg, but clinical practice guidelines for older adults and pain management recommend the more conservative 2 mg starting dose to minimize adverse effects 3, 2.
Titration Schedule
- Week 1: 2 mg at bedtime
- Week 2: If tolerated, increase to 2 mg twice daily (morning and evening)
- Weeks 3-4: Increase by 2-4 mg increments every 3-7 days
- Target dose: 6-8 mg three times daily (18-24 mg/day total)
- Maximum: 36 mg/day in divided doses 1, 2
The effect peaks at 1-2 hours and dissipates between 3-6 hours, necessitating dosing every 6-8 hours for sustained benefit 2.
Evidence for Cervical Radiculopathy
While tizanidine is FDA-approved for spasticity, not specifically for radiculopathy, there is supporting evidence for its use in neuropathic and myofascial pain conditions 4, 5, 6. An open-label study demonstrated that tizanidine (mean effective dose 23 mg/day, range 6-36 mg/day) reduced neuropathic pain scores significantly, with 68% of patients reporting improved or much improved pain relief 5. For chronic pain conditions, the typical effective dose ranges from 18-24 mg/day divided into three doses 1, 3.
Critical Safety Considerations
Contraindications and Cautions
- Absolute contraindication: Concomitant use with ciprofloxacin or fluvoxamine (CYP1A2 inhibitors) 1, 7
- Relative contraindications: Hepatic or renal impairment, elderly patients, concurrent use of oral contraceptives or other CYP1A2 inhibitors 1, 7
- Avoid with methadone: Increased risk of QTc prolongation 1
Monitoring Requirements
- Liver function tests: Monitor aminotransferases at baseline and during the first 6 months of treatment 2
- Blood pressure: Monitor closely, especially during titration, as two-thirds of patients experience 20% reduction in BP within 1-3 hours of dosing 2
- Orthostatic vital signs: Assess when moving from supine to standing 2
Common Adverse Effects
Expect dose-dependent sedation (47%), dizziness (24%), dry mouth (23%), and weakness (19%) 1, 7. These typically improve with continued use but may necessitate dose reduction.
Withdrawal Risk
Never stop abruptly if used for more than 9 weeks—taper slowly over several weeks to avoid rebound hypertension, tachycardia, and hypertonia 1, 7. This is a critical safety consideration often overlooked in clinical practice.
Food Effects
Food significantly alters tizanidine pharmacokinetics 2. Maintain consistency—either always take with food or always take on an empty stomach. Switching between fed and fasted states can cause unpredictable changes in drug levels, leading to increased adverse effects or loss of efficacy.
Special Populations
Elderly patients: Maximum 2 mg three times daily (6 mg/day total) due to increased sensitivity to sedative and hypotensive effects 3, 7. Consider even lower starting doses of 2 mg once daily.
Renal/hepatic impairment: Dose reduction required; close monitoring essential 1, 2.
Clinical Context
For chronic cervical radiculopathy specifically, evidence supports a multimodal approach including physical therapy, exercise, and potentially epidural corticosteroids for acute exacerbations 8, 9. Tizanidine serves as an adjunctive agent when muscle spasm or myofascial components contribute to pain. There is limited high-quality evidence for any single pharmacologic agent in cervical radiculopathy 8, 9, but tizanidine's mechanism as an α2-adrenergic agonist with central muscle relaxant properties makes it a reasonable option when conservative measures alone are insufficient 4, 5.
The typical treatment duration should be time-limited (8-12 weeks initially) with reassessment of continued need, as long-term data beyond 24-36 mg/day are limited 2.